2022 Participants

Home » 2022 Participants

Discover who attended BioFIT 2022

2022 Sponsors

Platinum sponsors

Globe Linkedin Twitter Facebook Instagram

Merck

We deliver the industry’s most comprehensive portfolio of high-quality products, services and testing for biopharmaceutical manufacturing.

We are proud to provide drug manufacturers with process development expertise and technologies, such as continuous bioprocessing.

We collaborate with the world’s leading drug developers to help bring drug therapies to patients. We bring our pharmaceutical and biotechnology expertise and products to improve every step of the manufacturing process, while providing startups with holistic support to build and scale up theirs.

Globe Linkedin Twitter Facebook Instagram

Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our teams across the world strive to transform the practice of medicine, turning the impossible into the possible for patients. We provide potentially life-changing treatments and the protection of life-saving vaccines to millions of people, and affordable access to our medicines in some of the world’s poorest countries.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Sanofi’s presentation “Why partner with Sanofi?”
Speaker: Murielle Gitton, Head R&D Transactions
Tuesday, November 29th | 3.15 – 3.30 pm | Innov’Area

Globe Linkedin Twitter Facebook Instagram

Sartorius

Sartorius Stedim Biotech is a leading partner of the biopharma industry. Our solutions are supporting our customers to produce drugs safely, timely and economically. The key product categories of our company are cell cultivation, fermentation, filtration, purification, and fluid management.

Sartorius’ presentation « Cell culture media and testing solution capabilities »
Speaker: Luka Kadovic, Field Application Specialist CMTS
Wednesday, November 30th | 11.45 am – 12.00 pm | Madrid 1 room

Globe Linkedin Twitter Facebook Instagram

Zoetis

Zoetis is the world’s leading animal health company. Our purpose is to nurture our world and humankind by advancing care for animals. After more than 70 years innovating ways to predict, prevent, detect, and treat animal illness, we continue to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. A Fortune 500 company, we generated revenue of $8.5 billion in 2023 with ~14,100 employees. For more, visit http://www.zoetis.com

Partnering with Zoetis

We strive to be the partner of choice in the vibrant and growing animal health industry. We collaborate with partners across the life sciences industries and academia, at any stage of development, from early research to commercial products – all with a shared interest in developing innovative solutions to improve the health and wellbeing of animals and the people who care for them.

Our areas of partnering interest

Livestock health
Companion animal therapeutics, including osteoarthritis, chronic pain, renal health, allergy and dermatitis
Preventatives
Diagnostics and Genetics
Platform technologies in biopharma, formulation, biomarkers and target discovery
Digital and Data Solutions

Silver sponsors

Globe Linkedin Twitter Facebook Instagram

Boehringer Ingelheim

As an independent company active in both human and animal health, Boehringer Ingelheim has learned over generations that the challenging path towards health innovation requires long-term commitment, resilience, and transformative action. Decades of cutting-edge science and innovation has enabled us to deliver many pioneering breakthroughs in some of the most devastating diseases and challenging areas we face globally. Continuing this journey hinges on collaboration.

We believe that working together with our global community of partners brings critical diversity to innovation and accelerates the next breakthroughs in human and animal health that will transform lives now and in generations to come. This collective power, in the tireless pursuit of science and solutions, enables us to build together a healthier, more sustainable, and equitable tomorrow.

Globe Linkedin Twitter Facebook Instagram

FINDMED

FINDMED is a consortium of 18 French leading research institutions involved in healthcare at large and that have got the “Carnot” label for their ability to conduct R&D partnerships with companies . FINDMED’s mission is to help French companies, in particular start-up and SMEs, to access the expertise and the technological platforms of its members. FINDMED is therefore companies’ R&D partner for their innovation projects, whether they be biotech and/or medtech.

Globe Linkedin Twitter Facebook Instagram

GENFIT

GENFIT is a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT has built up a diversified and rapidly expanding R&D portfolio of programs at various stages of development. The Company focuses on Acute-on-Chronic Liver Failure (ACLF). Its ACLF franchise includes five assets under development. Other assets target other life-threatening disease indications such as cholangiocarcinoma (CCA) and Urea Cycle Disorders (UCD)/Organic Acidemias (OA).

Globe Linkedin Twitter Facebook Instagram

Servier

Servier is a global independent pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 B€ in 2021, Servier employs 21,800 people worldwide. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. Servier growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neurosciences and immuno-inflammatory diseases.

More information: www.servier.com

Bronze sponsors

Globe Linkedin Twitter Facebook Instagram

ACROBiosystems

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation.

The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China.

Globe Linkedin Twitter Facebook Instagram

Capital Grand Est

Capital Grand Est is an asset management company based in Strasbourg – France.
The company manages over €180M.
Capital Grand Est is mainly focused on investing in growing SMEs and promising young Start-Ups located in the eastern part of France.

Globe Linkedin Twitter Facebook Instagram

Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit www.ipsen.com.

Our partnering team look forward to seeing you.

Globe Linkedin Twitter Facebook Instagram

MSD

MSD’s success stems from translating research into life-saving medical breakthroughs. From our development of the first measles and mumps vaccines to treatments for cancer and diabetes, we’ve become an industry leader in bringing innovative new medicines to patients. Approximately half of our pipeline is attributable to acquisitions, alliance partnerships and patents with our team executing 76 significant business development transactions in 2023. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life. Learn more at www.merck.com/licensing.

Globe Linkedin Twitter Facebook Instagram

Pfizer

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us.

Globe Linkedin Twitter Facebook Instagram

Pfizer CenterOne

Pfizer CentreOne® is a global CDMO within Pfizer and a leading supplier of specialty APIs. Our global manufacturing network includes more than 35 sites across six continents. Backed by Pfizer resources, we deliver technical expertise, global regulatory support and long-term supply.

Working together with our customers, we combine our knowledge with open dialogue to solve challenges. For more information, visit www.pfizercentreone.com.

Globe Linkedin Twitter Facebook Instagram

Roche

Roche is a leading healthcare company and is heavily investing into R&D, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the CNS. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare. Our Pharma Partnering team provides comprehensive BD and alliance management support for Roche and Genentech’s R&D units and the broader pharmaceutical division. Alongside the broad internal pipeline, external innovation has always been a critical component of our R&D strategy.

Globe Linkedin Twitter Facebook Instagram

X’Prochem

Founded in 2012, X’PROCHEM is a CRO (Contract Research Organization) specializied in chemical protein synthesis.

We design and produce therapeutic proteins for our pharmaceutical and biotech partners. We manufacture complex and highly customized proteins up to 400 amino acids (40 kDa) by using an automated process.

Contributing sponsors

Globe Linkedin Twitter Facebook Instagram

AdBio

AdBio partners (formerly Advent France Biotechnology) is a venture capital firm investing in early stage life sciences companies in Europe

AdBio partners’ unique strategy combines early-stage investments in promising startups and strong entrepreneurial support to enable and strengthen the company’s growth.

As an early-stage investor, we act as a catalyst to create companies based on innovations coming from academic research. We have established relationships with leading research institutions and technology transfer offices in Europe and benefit from the support of strong network of scientific, clinical, industry and financial partners.

The operational team is managed by Alain Huriez, MD, chairman, and Matthieu Coutet, managing partner; it includes seasoned investment professionals with long-standing track records in entrepreneurial ventures, combined with strong scientific and medical expertise.

Globe Linkedin Twitter Facebook Instagram

Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases such as diabetes, obesity and cardiovascular disease as well as rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease.